EA
ANIP icon

Emerald Acquisition’s ANI Pharmaceuticals ANIP Stock Holding History

Emerald Acquisition’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$897K Hold
13,519
– – ﹤0.01% 2180
2016
Q2 		$755K Buy
+13,519
New +$657K ﹤0.01% 2310

Other funds holding ANIP

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return

Emerald Acquisition's ANIP Position: Q3 2016 in Review

Emerald Acquisition held its ANI Pharmaceuticals (ANIP) position steady in Q3 2016 at 13,519 shares worth $897K. The position accounts for ﹤0.01% of the portfolio, ranked #2180.

Emerald Acquisition first reported a position in ANIP in Q2 2016 and has held it in 2 quarters since. 170 funds tracked by Wall St. Rank hold ANIP as of Q3 2016.

  • Emerald Acquisition held 13,519 shares of ANI Pharmaceuticals worth $897K as of Q3 2016.
  • Emerald Acquisition left its ANI Pharmaceuticals share count unchanged in Q3 2016.
  • ANI Pharmaceuticals made up ﹤0.01% of Emerald Acquisition's portfolio in Q3 2016, its #2180 holding.
  • Emerald Acquisition first reported a position in ANI Pharmaceuticals in Q2 2016 and has held it in 2 quarters since.
  • 170 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.